Oncotarget

Research Papers:

Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status

He-Sheng Jiang, Xia-Ying Kuang, Wei-Li Sun, Yan Xu, Yi-Zi Zheng, Yi-Rong Liu, Guan-Tian Lang, Feng Qiao, Xin Hu and Zhi-Ming Shao _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:41285-41293. https://doi.org/10.18632/oncotarget.9778

Metrics: PDF 1112 views  |   HTML 1387 views  |   ?  


Abstract

He-Sheng Jiang1,2,*, Xia-Ying Kuang1,5,*, Wei-Li Sun2,*, Yan Xu4, Yi-Zi Zheng1,2, Yi-Rong Liu1,2, Guan-Tian Lang1,2, Feng Qiao2, Xin Hu2 and Zhi-Ming Shao1,2,3

1 Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

3 Institutes of Biomedical Science, Fudan University, Shanghai, China

4 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China

5 Department of Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

* These authors have contributed equally to this article

Correspondence to:

Zhi-Ming Shao, email:

Xin Hu, email:

Keywords: breast cancer; TNBC; androgen receptor; BRCA1; hormone receptor

Received: February 26, 2016 Accepted: May 20, 2016 Published: June 07, 2016

Abstract

In this study we sought to correlate androgen receptor (AR) expression with tumor progression and disease-free survival (DFS) in breast cancer patients. We investigated AR expression in 450 breast cancer patients. We found that breast cancers expressing the estrogen receptor (ER) are more likely to co-express AR compared to ER-negative cancers (56.0% versus 28.1%, P < 0.001). In addition, we found that AR expression is correlated with increased DFS in patients with luminal breast cancer (P < 0.001), and decreased DFS in TNBC (triple negative breast cancer, P = 0.014). In addition, patients with HR+ tumors (Hormone receptor positive tumors) expressing low levels of AR have the lowest DFS among all receptor combinations. We also propose a novel prognostic model using AR receptor status, BRCA1, and present data showing that our model is more predictive of disease free survival compared to the traditional TMN staging system.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9778